Brief: Race Oncology Seeks Trading Halt Pending Announcement On Clinical Results For Dose Escalation Phase Of 1B/2 Zantrene Aml Trial In Israel
26/05/2022 07:15
May 26 (Reuters) - Race Oncology Ltd RAC.AX :
* SEEKS TRADING HALT PENDING ANNOUNCEMENT ON CLINICAL
RESULTS FOR
DOSE ESCALATION PHASE OF 1B/2 ZANTRENE AML TRIAL IN ISRAEL
Source text for Eikon: ID:nASX93ZSp6
Further company coverage: RAC.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Racura Oncology
See all newsAustralia's Racura Oncology jumps most in a month after raising $24 million
Brief: Racura Oncology Says Emerging Companies Specialist Invests In Racura
Brief: Racura Oncology Announces Positive Safety Review Committee Recommendation In Ongoing Cpacs Clinical Trial
Australia's Racura Oncology gains on Purdue University cancer study collab
Brief: Racura Oncology Receives Governance Approval For Harness-1 Phase 1 Trial Of Rc220